Literature DB >> 15380268

Development of macrolide-resistance and comparative activity of telithromycin in streptococci in Austria, 1996-2002.

Astrid Buxbaum1, Sabine Forsthuber, Robert Sauermann, Rainer Gattringer, Wolfgang Graninger, Apostolos Georgopoulos.   

Abstract

The increase detected in macrolide resistance in streptococci in various parts of the world has brought into question the usefulness of macrolides as first line therapy for respiratory tract infections. In a nationwide study, a total of 3012 Streptococcus pneumoniae and 499 Streptococcus pyogenes isolates were collected from 1996 to 2002 and tested for their susceptibility to penicillin, azithromycin, clarithromycin and telithromycin (2002 only). Penicillin-intermediate and -resistant isolates of S. pneumoniae comprised 4.9% (2.9 and 2.0%, respectively) of all isolates in 1996; macrolide resistance was also comparatively low at 3.2%. In the following years the rate of penicillin-resistant pneumococci increased steadily, reaching the 10% mark in 2002. A similar trend was recorded for the macrolides. No penicillin-resistant strain of S. pyogenes was found during the observation period. The prevalence of macrolide-resistance in S. pyogenes climbed from 4.7% in 1996 to the present rate of 7.2% (clarithromycin) and 9.4% (azithromycin). Telithromycin showed excellent activity against both S. pneumoniae and S. pyogenes with 99.8 and 100% strains sensitive, respectively.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15380268     DOI: 10.1016/j.ijantimicag.2004.04.010

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  4 in total

Review 1.  [Sense and nonsense in antibiotic therapy for respiratory tract infections].

Authors:  W Domej; E Flögel; G P Tilz; U Demel
Journal:  Internist (Berl)       Date:  2005-07       Impact factor: 0.743

2.  Evaluation of the Potency, Neutralizing Antibody Response, and Stability of a Recombinant Fusion Protein Vaccine for Streptococcus pyogenes.

Authors:  E Burlet; H HogenEsch; A Dunham; G Morefield
Journal:  AAPS J       Date:  2017-03-10       Impact factor: 4.009

Review 3.  Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options.

Authors:  Françoise Van Bambeke; René R Reinert; Peter C Appelbaum; Paul M Tulkens; Willy E Peetermans
Journal:  Drugs       Date:  2007       Impact factor: 9.546

4.  Vaccine based on a ubiquitous cysteinyl protease and streptococcal pyrogenic exotoxin A protects against Streptococcus pyogenes sepsis and toxic shock.

Authors:  Robert G Ulrich
Journal:  J Immune Based Ther Vaccines       Date:  2008-10-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.